Share
 
Title
Code
Session Type
Venue
Date Time
Co-Chairs:

This session addresses the latest data and progress on HIV vaccines and antibody prophylaxis, with a focus on candidates that are currently in or soon to begin efficacy trials, particularly in southern Africa. Presentations provide summaries of the latest data on Pox Protein Public Private Partnership (P5) which is the follow up studies to RV144, Antibody Mediated Prevention (AMP), the Ad26/MVA programme and the current phase 1 pipeline. The session will commence with the hand out of the IAS 2016 Presidential Award to Dr. Anthony Fauci for his longstanding leadership and excellence at the forefront of the response. This session is directed to basic science researchers, clinicians and prevention researchers interested in vaccine research. At the completion of the session, the participants will have a comprehensive understanding of current and imminent proof-of-concept HIV vaccine trials as well as new concepts currently at the pre-clinical or phase 1 stage.

11:00
TUSY0301
Introduction
Wendy Anne Burgers, University of Cape Town, South Africa
Slides

11:03
TUSY0302
IAS President's Award
Chris Beyrer, Johns Hopkins University, United States
Amy Lansky, Office of National AIDS Policy, United States
Slides

11:08
TUSY0303
Remarks
Anthony Fauci, National Institutes of Health (NIH), United States
Slides

11:18
TUSY0304
P5 (Pox Protein Public Private Partnership) vaccine programme
Fatima Laher, University of the Witwatersrand, South Africa

11:33
TUSY0305
The AMP Study (Antibody Mediated Prevention)
Nyaradzo Mavis Mgodi, University of Zimbabwe, Zimbabwe
Slides

11:48
TUSY0306
Heterologous vaccination with Ad26/MVA
Hanneke Schuitemaker, Janssen Vaccines & Prevention, Netherlands
Slides

12:03
TUSY0307
New HIV vaccine concepts
Nicole Frahm, Fred Hutchinson Cancer Research Center, United States

12:18
TUSY0308
Questions and answers
12:28
TUSY0309
Conclusion